echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Express treatment of HER2-positive breast cancer, blockbuster ADC has made positive progress

    Express treatment of HER2-positive breast cancer, blockbuster ADC has made positive progress

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎Edited by WuXi AppTec Content Team

    AstraZeneca and Daiichi Sankyo announced today that their Antibody Drug Conjugate (ADC) Enhertu (trastuzumab deruxtecan) has entered the DESTINY-Breast02 Phase 3 trial in patients with unresectable or metastatic breast cance.



    Breast cancer is one of the most common forms of cance.


    [1] ENHERTU® Significantly Delayed Disease Progression in DESTINYBreast02 Phase 3 Trial Versus Physician's Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cance.



    Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progres.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.